Drug discovery and the use of computational approaches for infectious diseases

Future Medicinal Chemistry

Volumn 3, Issue 8, 2011, Pages 1011-1025

  Marhöfer, Richard J ^a   Oellien, Frank ^a   Selzer, Paul M ^a  

^a Intervet Innovation GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARASITIC AGENT;

AFRICAN TRYPANOSOMIASIS; BINDING SITE; COMPUTER MODEL; DRUG ACTIVITY; DRUG DESIGN; DRUG REPOSITIONING; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; GENE INACTIVATION; GENOME ANALYSIS; HUMAN; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR PHYLOGENY; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SEQUENCE ANALYSIS;

ANIMALS; ANTIPARASITIC AGENTS; COMMUNICABLE DISEASES; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR;

EID: 79959807075     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.60     Document Type: Review

References (99)

1. Selzer PM: Preface. In: Antiparasitic and Antibacterial Drug Discovery - From Molecular Targets to Drug Candidates. Selzer PM (Ed.Wiley-VCH, Weinheim, Germany XI-XII (2009
2. McKerrow JH. Foreword. In: Antiparasitic and Antibacterial Drug Discovery - From Molecular Targets to Drug Candidates. Selzer PM (Ed.Wiley-VCH, Weinheim, Germany, V (2009
3. Connor RJ. The impact of nagana. Onderstepoort J. Vet. Res. 61, 379-383 (1994
4. Sachs J, Malaney P. The economic and social burden of malaria. Nature 415, 680-685 (2002 (Pubitemid 34136401)
5. Renslo AR, McKerrow JH. Drug discovery and development for neglected parasitic diseases. Nat. Chem. Biol. 2, 701-710 (2006 (Pubitemid 44764212)
6. Krasky A, Rohwer A, Marhöfer RJ, Selzer PM. Bioinformatics and chemoinformatics: key technologies in the drug discovery process. In: Antiparasitic and Antibacterial Drug Discovery - from Molecular Targets to Drug Candidates. Selzer PM (Ed.Wiley-VCH, Weinheim, Germany 45-57 (2009
7. Simmons KJ, Chopra I, Fishwick CW. Structure-based discovery of antibacterial drugs. Nat. Rev. Microbiol. 8(7), 501-510 (2010
8. Mardini IA, FitzGerald GA. Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs. Mol. Interv. 1(1), 30-38 (2001
9. Stratton MS, Alberts DS. Current application of selective COX-2 inhibitors in cancer prevention and treatment. Oncology (Williston Park, NY) 16(5 Suppl. 4), 37-51 (2002
10. Traxler P, Bold G, Buchdunger E et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev. 21(6), 499-512 (2001 (Pubitemid 32959239)
11. Kaldor SW, Kalish VJ, Davies JF et al. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40(24), 3979-3985 (1997 (Pubitemid 27512316)
12. Highleyman L. New anti-HIV drugs in development. BETA 12(2), 7-8 (1999
13. Ghosh AK, Dawson ZL, Mitsuya H. Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorg. Med. Chem. 15(24), 7576-7580 (2007 (Pubitemid 47575929)
14. Ghosh AK, Ramu SP, Kumaragurubaran N, Koh Y, Weber IT, Mitsuya H. Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of HIV protease inhibitors that combat drug resistance. ChemMedChem 1(9), 939-950 (2006 (Pubitemid 44448791)
15. Specker E, Bottcher J, Brass S et al. Unexpected novel binding mode of pyrrolidine-based aspartyl protease inhibitors: design, synthesis and crystal structure in complex with HIV protease. ChemMedChem 1(1), 106-117 (2006 (Pubitemid 44104983)
16. Specker E, Bottcher J, Lilie H et al. An old target revisited: two new privileged skeletons and an unexpected binding mode for HIV-protease inhibitors. Angew. Chem. Int. Ed. Engl. 44(20), 3140-3144 (2005 (Pubitemid 40689862)
17. Dorsey BD, Levin RB, McDaniel SL et al. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37(21), 3443-3451 (1994 (Pubitemid 24334599)
18. Erickson J, Neidhart DJ, VanDrie J et al. Design, activity, and 2.8 Å crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 249(4968), 527-533 (1990
19. Roberts NA, Martin JA, Kinchington D et al. Rational design of peptide-based HIV proteinase inhibitors. Science 248(4953), 358-361 (1990
20. Giersiefen H, Hilgenfeld R, Hillisch A. Modern methods of drug discovery: an introduction. In: Modern Methods of Drug Discovery. Hillisch A, Hilgenfeld R (EdsBirkhäuser Verlag, Basel, Switzerland 1-18 (2002
21. Keil M, Marhöfer RJ, Rohwer A, Selzer PM, Korb O, Exner TE. Molecular visualization in the rational drug design process. Front. Biosci. 14, 2559-2583 (2009
22. Rohwer A, Marhöfer RJ, Caffrey CR, Selzer PM. Drug-discovery approaches towards anti-parasitic agents. In: Apicomplexan Parasites - Molecular Approaches toward Targeted Drug Development. Becker K. (Ed.Wiley-VCH, Weinheim, Germany 3-20 (2011
23. Caffrey CR, Rohwer A, Oellien F et al. A comparative chemogenomics strategy to predict potential drug targets in the metazoan pathogen, Schistosoma mansoni. PLoS One 4(2), e4413 (2009
24. Hopkins AL, Groom CR. The druggable genome. Nat. Rev. Drug Discov. 1(9), 727-730 (2002 (Pubitemid 37361545)
25. Russ AP, Lampel S. The druggable genome: an update. Drug Discov. Today 10(23-24), 1607-1610 (2005 (Pubitemid 41817609)
26. Edfeldt FN, Breeze AL, Folmer RH. Fragment screening to predict druggability (ligandability) and lead discovery success. Drug Discov. Today (2011
27. Abdulla MH, Lim KC, Sajid M, KcKerrow JH, Caffrey CR. Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Medicine 4(1), e14 (2007
28. Engel JC, Doyle PS, Hsieh I, McKerrow JH. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med. 188, 725-734 (1998 (Pubitemid 28387935)
29. Robinson MW, McFerran N, Trudgett A, Hoey L, Fairweather I. A possible model of benzimidazole binding to beta-tubulin disclosed by invoking an inter-domain movement. J. Mol. Graph. Model. 23(3), 275-284 (2004 (Pubitemid 39463106)
30. Selzer PM, Pingel S, Hsieh I et al. Cysteine protease inhibitors as chemotherapy: lessons from a parasite target. Proc. Natl Acad. Sci. USA 96(20), 11015-11022 (1999 (Pubitemid 29487320)
31. Iten M, Mett H, Evans A, Enyaru JC, Brun R, Kaminsky R. Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to d,l-a-difluoromethylornithine. Antimicrob. Agents Chemother. 41(9), 1922-1925 (1997 (Pubitemid 27383228)
32. Zhang K, Rathod PK. Divergent regulation of dihydrofolate reductase between malaria parasite and human host. Science 296(5567), 545-547 (2002 (Pubitemid 34408676)
33. Clough B, Rangachari K, Strath M, Preiser PR, Wilson RJ. Antibiotic inhibitors of organellar protein synthesis in Plasmodium falciparum. Protist. 150(2), 189-195 (1999 (Pubitemid 29442459)
34. Utzinger J, Keiser J. Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. Expert Opin. Pharmacother. 5(2), 263-285 (2004 (Pubitemid 38219854)
35. Schnyder M, Torgerson PR, Schonmann M, Kohler L, Hertzberg H. Multiple anthelmintic resistance in Haemonchus contortus isolated from South African Boer goats in Switzerland. Vet. Parasitol. 128(3-4), 285-290 (2005 (Pubitemid 40312437)
36. Dartois V, Leong FJ, Dick T. Tuberculosis drug discovery: issues, gaps and the way forward. In: Antiparasitic and Antibacterial Drug Discovery - from Molecular Targets to Drug Candidates. Selzer PM (Ed.Wiley- VCH, Weinheim, Germany 415-440 (2009)
37. Zhang Y, Amzel LM. Tuberculosis drug targets. Curr. Drug Targets 3(2), 131-154 (2002 (Pubitemid 34296204)
38. Shah F, Mukherjee P, Desai P, Avery M. Computational approaches for the discovery of cysteine protease inhibitors against malaria and SARS. Curr. Comput. Aided Drug Des. 6(1), 1-23 (2010
39. Hertz-Fowler C, Peacock CS, Wood V et al. GeneDB: a resource for prokaryotic and eukaryotic organisms. Nucleic Acids Res. 32(Database issue), D339-D343 (2004 (Pubitemid 38081672)
40. Chen X, Ji ZL, Chen YZ. TTD: therapeutic target database. Nucleic Acids Res. 30(1), 412-415 (2002 (Pubitemid 34679600)
41. Overington J. ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBIInterview by Wendy A Warr. J. Comput. Aided Mol. Des. 23(4), 195-198 (2009
42. Chen L, Oughtred R, Berman HM, Westbrook J. TargetDB: a target registration database for structural genomics projects. Bioinformatics 20(16), 2860-2862 (2004 (Pubitemid 39530181)
43. Gao Z, Li H, Zhang H et al. PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics 9, 104-110 (2008
44. Aurrecoechea C, Brestelli J, Brunk BP et al. EuPathDB: a portal to eukaryotic pathogen databases. Nucleic Acids Res. 38(Database issue), D415-D419 (2010
45. Aguero F, Al Lazikani B, Aslett M et al. Genomic-scale prioritization of drug targets: the TDR targets database. Nat. Rev. Drug Discov. 7(11), 900-907 (2008
46. Roberts CW, Henriquez FL. Drug target identification, validation, characterisation and exploitation for treatment of Acanthamoeba (species) infections. Exp. Parasitol. 126(1), 91-96 (2010
47. Henriquez FL, Ingram PR, Muench SP, Rice DW, Roberts CW. Molecular basis for resistance of Acanthamoeba tubulins to all major classes of antitubulin compounds. Antimicrob. Agents Chemother. 52(3), 1133-1135 (2008 (Pubitemid 351358398)
48. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3(8), 673-683 (2004 (Pubitemid 39173508)
49. Geary TG, Woods DJ, Williams T, Nwaka S. Target identification and mechanism-based screening for anthelmintics: application of veterinary antiparasitic research programs to search for new antiparasitic drugs for human indications. In: Antiparasitic and Antibacterial Drug Discovery - from Molecular Targets to Drug Candidates. Selzer PM (Ed.Wiley- VCH, Weinheim, Germany 3-16 (2009
50. Miculka C, Tran H, Meyer T et al. Orlistat: a repositioning opportunity as a growth inhibitor of apicomplexan parasites? In: Apicomplexan Parasites - Molecular Approaches Toward Targeted Drug Development. Becker K. (Ed.Wiley-VCH, Weinheim, Germany 481-492 (2011
51. Ekins S, Williams AJ, Krasowski MD, Freundlich JS. In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov. Today 16(7-8), 298-310 (2011
52. Hohman M, Gregory K, Chibale K, Smith PJ, Ekins S, Bunin B. Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery. Drug Discov. Today 14(5-6), 261-270 (2009
53. Kinnings SL, Liu N, Buchmeier N, Tonge PJ, Xie L, Bourne PE. Drug discovery using chemical systems biology: repositioning the safe medicine comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput. Biol. 5(7) (2009
54. Alfarano C, Andrade CE, Anthony K et al. The Biomolecular Interaction Network Database and related tools 2005 update. Nucleic Acids Res. 33 (Database issue), D418-D424 (2005
55. Li H, Gao Z, Kang L et al. TarFisDock: a web server for identifying drug targets with docking approach. Nucleic Acids Res. 34 (Web server issue), W219-W224 (2006 (Pubitemid 44529767)
56. Liu X, Ouyang S, Yu B et al. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res. 38 (Web server issue), W609-W614 (2010
57. Jaeger T, Flohe L. The thiol-based redox networks of pathogens: unexploited targets in the search for new drugs. Biofactors 27(1-4), 109-120 (2006 (Pubitemid 44444593)
58. Koch O, Jaeger T, Flohé L, Selzer PM. Virtual screening by high-throughput docking using hydrogen binding constraints for targeting a protein-protein interface in M. tuberculosis. J. Cheminform. 2(Suppl. 1), 24 (2010
59. Beig M, Bender F, Oellien F, Gassel M, Selzer PM. Trypanothione reductase: a target protein for a combined in silico and in vitro screening approach. In: Flavins and Flavoproteins 2008. Frago S, Gómez-Moreno C, Medina M (EdsPrensas Universitarias de Zaragoza, Zaragoza, Spain 503-508 (2008
60. Krasky A, Rohwer A, Schroeder J, Selzer PM. A combined bioinformatics and chemoinformatics approach for the development of new antiparasitic drugs. Genomics 89(1), 36-43 (2007 (Pubitemid 44873185)
61. Hasan S, Daugelat S, Rao PS, Schreiber M. Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. PLoS Comput. Biol. 2(6), e61 (2006
62. Crowther GJ, Shanmugam D, Carmona SJ et al. Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. PLoS Negl. Trop. Dis. 4(8), e804 (2010
63. Kumar S, Chaudhary K, Foster JM et al. Mining predicted essential genes of Brugia malayi for nematode drug targets. PLoS One 2(11), e1189 (2007
64. Beckstette M, Mailaender JT, Marhoefer RJ et al. Genlight: interactive high-throughput sequence analysis and comparative genomics. J. Integr. Bioinform. 1, 8 (2004
65. Ren JY, Xie L, Li WW, Bourne PE. SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison. Nucleic Acids Res. 38, W441-W444 (2010
66. Xie L, Bourne PE. Detecting evolutionary relationships across existing fold space, using sequence order-independent profile-profile alignments. Proc. Natl Acad. Sci. USA 105(14), 5441-5446 (2008 (Pubitemid 351753882)
67. Bakheet TM, Doig AJ. Properties and identification of antibiotic drug targets. BMC Bioinformatics 11, 195 (2010
68. Han LY, Zheng CJ, Xie B et al. Support vector machines approach for predicting druggable proteins: recent progress in its exploration and investigation of its usefulness. Drug Discov. Today 12(7-8), 304-313 (2007 (Pubitemid 46476873)
69. Li QL, Lai LH. Prediction of potential drug targets based on simple sequence properties. BMC Bioinformatics 8, 353 (2007
70. Zhang HL, Lin HH, Tao L et al. Prediction of antibiotic resistance proteins from sequence-derived properties irrespective of sequence similarity. Int. J. Antimicrob. Agents 32(3), 221-226 (2008
71. Wishart DS, Knox C, Guo AC et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36, D901-D906 (2008 (Pubitemid 351149842)
72. Bairoch A, Apweiler R. The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000. Nucleic Acids Res. 28(1), 45-48 (2000 (Pubitemid 30047711)
73. Guvench O, MacKerell AD Jr. Computational evaluation of protein-small molecule binding. Curr. Opin. Struct. Biol. 19(1), 56-61 (2009
74. Good AC, Mason JS, Pickett SD. Pharmacophore pattern application in virtual screening, library design and QSAR. In: Virtual Screening for Bioactive Molecules. Böhm H-J, Schneider G, Mannhold R, Kubinyi H, Timmermann H (EdsWiley-VCH, Weinheim, Germany 131-156 (2000
75. Zamecnikova A. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer. Expert Rev. Hematol. 3(1), 45-56 (2010
76. Nguyen-Van-Tam JS. Foreword: oseltamivir for seasonal, avian and pandemic influenza: 10 years of clinical experience. J. Antimicrob. Chemother. 65(Suppl. 2), ii3-ii4 (2010
77. Sansom C. Molecules made to measure. Chemistry World 6(11), 50-53 (2009
78. Volarath P, Harrison RW, Weber IT. Structure based drug design for HIV protease: from molecular modeling to cheminformatics. Curr. Top. Med. Chem. 7(10), 1030-1038 (2007 (Pubitemid 47040530)
79. Engels K, Beyer C, Suarez Fernandez ML et al. Inhibition of Eimeria tenella CDK-related kinase 2: from target identification to lead compounds. ChemMedChem 5(8), 1259-1271 (2010
80. Guido RV, Oliva G, Montanari CA, Andricopulo AD. Structural basis for selective inhibition of trypanosomatid glyceraldehyde- 3-phosphate dehydrogenase: molecular docking and 3D QSAR studies. J. Chem. Inf. Model. 48(4), 918-929 (2008 (Pubitemid 351757757)
81. Guido RV, Oliva G. Structure-based drug discovery for tropical diseases. Curr. Top. Med. Chem. 9(9), 824-843 (2009
82. Postigo MP, Guido RV, Oliva G et al. Discovery of new inhibitors of Schistosoma mansoni PNP by pharmacophore-based virtual screening. J. Chem. Inf. Model. 50(9), 1693-1705 (2010
83. Dalloul RA, Lillehoj HS. Poultry coccidiosis: recent advancements in control measures and vaccine development. Expert Rev. Vaccines 5(1), 143-163 (2006
84. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9(3), 153-166 (2009
85. Monaco EA III, Vallano ML. Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians. Curr. Med. Chem. 10(5), 367-379 (2003 (Pubitemid 36221570)
86. Tamamori M, Ito H, Hiroe M, Terada Y, Marumo F, Ikeda MA. Essential roles for G1 cyclin-dependent kinase activity in development of cardiomyocyte hypertrophy. Am. J. Physiol. 275(6 Pt 2), H2036-H2040 (1998
87. Schang.LM, St Vincent MR, Lacasse JJ. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antiviral Chem. Chemother. 17, 293-320 (2010 (Pubitemid 46043181)
88. Doerig C, Chakrabarti D, Kappes B, Matthews K. The cell cycle in protozoan parasites. Prog. Cell Cycle Res. 4, 163-183 (2000
89. Kinnaird JH, Bumstead JM, Mann DJ et al. EtCRK2, a cyclin-dependent kinase gene expressed during the sexual and asexual phases of the Eimeria tenella life cycle. Int. J. Parasitol. 34(6), 683-692 (2004 (Pubitemid 38521223)
90. Brooijmans N, Kuntz ID. Molecular recognition and docking algorithms. Annu. Rev. Biophys. Biomol. Struct. 32, 335-373 (2003 (Pubitemid 37056233)
91. Krieger E, Nabuurs SB, Vriend G. Homology modeling. Methods Biochem. Anal. 44, 509-523 (2003
92. Gao HX, Peng LM. Parameterization of the temperature dependence of the Debye-Waller factors. Acta Crystallogr. A 55, 926-932 (1999
93. Villoutreix BO, Eudes R, Miteva MA. Structure-based virtual ligand screening: recent success stories. Comb. Chem. High Throughput Screen. 12(10), 1000-1016 (2009).
94. Todeschini R, Consonni V. Handbook of Molecular Descriptors. Wiley-VCH, Weinheim, Germany (2000
95. Xue L, Bajorath J. Molecular descriptors in chemoinformatics, computational combinatorial chemistry, and virtual screening. Comb. Chem. High Throughput Screen. 3(5), 363-372 (2000
96. Hert J, Willett P, Wilton DJ et al. Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures. Org. Biomol. Chem. 2(22), 3256-3266 (2004
97. Aqvist J, Marelius J. The linear interaction energy method for predicting ligand binding free energies. Comb. Chem. High Throughput Screen. 4, 613-626 (2001 (Pubitemid 34003156)
98. Valeyev NV, Bates DG, Umezawa Y, Gizatullina AN, Kotov NV. Systems biology of cell behavior. Methods Mol. Biol. 662, 79-95 (2010
99. Saric J, Li JV, Utzinger J et al. Systems parasitology: effects of Fasciola hepatica on the neurochemical profile in the rat brain. Mol. Syst. Biol. 6, 396 (2010).